ACE Ascelia Pharma AB (publ)
0.8560SEK+22.29%Mkt Cap: 10.93M $P/E: —1d ago
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, wh…
Industry Peers
Biotechnology$127.47BUSDP/E 29.3
$78.65BUSD
$76.14BUSDP/E 18.3
$51.48BUSDP/E 31.2
$48.23BUSDP/E 31.4
$41.82BUSDP/E 17.8
$40.32BUSD
$39.83BUSDP/E 62.6
$32.48BUSDP/E 29.9
$30.04BUSDP/E 37.9
$24.71BUSD
$23.13BUSD
$22.85BUSDP/E 14.4
$22.17BUSDP/E 28.4
$21.94BUSD
$21.10BUSDP/E 29.1
$14.65BUSDP/E 17.1
$14.62BUSDP/E 18.6
$14.44BUSDP/E 15.2
$13.70BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
Ascelia Pharma AB (FRA:7ZA) (Q2 2026) Earnings Call Highlights: Navigating FDA Setback for ... Despite a surprise complete response letter, Ascelia Pharma remains confident in Orviglans' approval path, with a pivotal FDA Type A meeting set for September 9th and partnership interest intact. | ||